Level C· Early human research exploring benefitsRetrospective StudyPubMed

Comprehensive arthroscopic management procedure and autologous microfragmented adipose tissue infiltration in mild-to-moderate glenohumeral osteoarthritis: two-year follow-up outcomes.

Giorgini A., Addala H., De Pasquale L., Micheloni GM., Fregni U., Porcellini G.

Retrospective Study with a reported sample of 19 on Osteoarthritis, Shoulder Pain, published in JSES Rev Rep Tech (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
JSES Rev Rep Tech (2026)
Country
Netherlands
Reported sample size
19
Source database
PubMed
PMID
42389646
DOI
10.1016/j.xrrt.2026.100778

Abstract (original English)

The aim of this study was to evaluate clinical outcomes in patients with mild-to-moderate concentric glenohumeral osteoarthritis (GHOA) treated with arthroscopic surgery according to the Comprehensive Arthroscopic Management (CAM) procedure combined with intra-articular injection of autologous microfragmented adipose tissue (mFAT) (Lipogems). Since there was no CAM-only control group, the study does not assess the independent contribution of mFAT. In this retrospective study, 19 patients (mean age 52 years; 17 males, 2 females) with Samilson-Prieto grade 1-3 GHOA were included. All patients underwent arthroscopic CAM surgery followed by intra-articular injection of autologous mFAT. Primary outcomes were assessed using the visual analog scale for pain and the American Shoulder and Elbow Surgeons score at baseline (T 0 ) and at 1 (T 1 ), 3 (T 3 ), 6 (T 6 ), 12 (T 12 ), and 24 months (T 24 ) post-operatively. Significant improvements in both visual analog scale and American Shoulder and Elbow Surgeons scores were observed at 1 month and maintained up to 24 months ( P < .05). Patients aged ≤50 years or with grade 1-2 GHOA tended to experience greater clinical improvements. The observed improvements in pain and function exceeded published thresholds for the Minimal Clinically Important Difference and fell below the Patient Acceptable Symptom State, indicating that changes were not o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research